Infliximab, azathioprine, or combination therapy for Crohn's disease.

Detalles Bibliográficos
Publicado en:New England Journal of Medicine Vol. 363; no. 11; pp. 1086 - 1089
Autores principales: Gelber AC, Gelber, Allan C
Formato: commentary letter response Journal Article
Publicado: New England Journal of Medicine 9/9/2010
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105107698&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 105107698
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00284793
        NEJ
      jtl: New England Journal of Medicine
      issn: 00284793
      maglogo: N
    pubinfo:
      dt: 9/9/2010
      vid: 363
      iid: 11
      pid: 388
      pub: New England Journal of Medicine
      place: Waltham, Massachusetts
    artinfo:
      ui:
        105107698
        105107698
        NLM20848680
        2010797164
        10.1056/NEJMc1005805
        NLM20848680
        105107698
      ppf: 1086
      ppct: 3
      formats:
      tig:
        atl: Infliximab, azathioprine, or combination therapy for Crohn's disease.
      aug:
        au:
          Gelber AC
          Gelber, Allan C
      sug:
        subj:
          Antibodies, Monoclonal Therapeutic Use
          Azathioprine Therapeutic Use
          Crohn Disease Drug Therapy
          Immunosuppressive Agents Therapeutic Use
          Antiinflammatory Agents Therapeutic Use
          Arthritis Complications
          Arthritis Drug Therapy
          Drug Therapy, Combination
          Pyoderma Gangrenosum Complications
          Pyoderma Gangrenosum Drug Therapy
      pubtype: Academic Journal
      doctype:
        commentary
        letter
        response
        Journal Article
      ougenre: Unknown
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N